Mito-DEPMPO, a new DEPMPO analogue bearing a triphenylphosphonium group, was synthesized via a novel NH2-reactive DEPMPO. The half-life of the Mito-DEPMPO superoxide adduct was estimated to be ca. 40 min. Using Mito-DEPMPO, reactive oxygen species generated in intact mitochondria were detected and characterized by EPR.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/b616076j | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultrasonically Activated Liquid Metal Catalysts in Water for Enhanced Hydrogenation Efficiency.
ACS Appl Mater Interfaces
January 2025
Department of Chemistry and Materials Engineering, Kansai University, 3-3-35 Yamate-cho, Suita, Osaka 564-8680, Japan.
Hydride (H) species on oxides have been extensively studied over the past few decades because of their critical role in various catalytic processes. Their syntheses require high temperatures and the presence of hydrogen, which involves complex equipment, high energy costs, and strict safety protocols. Hydride species tend to decompose in the presence of atmospheric oxygen and water, which reduces their catalytic activities.
View Article and Find Full Text PDFNovel Dual-Functional Half-Curcumin Analogues as a Fluorescent and PET Probe for β-Amyloid Imaging in the Alzheimer's Disease APP/PS1 Model.
ACS Chem Neurosci
January 2025
School of Medicine, Shanghai University, Shanghai 200444, China.
Noninvasive imaging of β-amyloid is pivotal for the early diagnosis of Alzheimer's disease (AD). While single imaging methods have been extensively studied for detecting Aβ over the past decade, dual-modal probes have received scant attention. In this study, we synthesized and assessed a series of half-curcumin probes, among which demonstrated a high affinity and selectivity for Aβ aggregates.
View Article and Find Full Text PDFDevelopment of multifunctional fluorescence-emitting potential theranostic agents for Alzheimer's disease.
Talanta
January 2025
Pharmaceutical Chemistry Research Laboratory I, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, 221005, India. Electronic address:
The cholinergic deficits and amyloid beta (Aβ) aggregation are the mainstream simultaneously observed pathologies during the progression of Alzheimer's disease (AD). Deposited Aβ plaques are considered to be the primary pathological hallmarks of AD and are contemplated as promising diagnostic biomarker. Herein, a series of novel theranostic agents were designed, synthesised and evaluated against cholinesterase (ChEs) enzymes and detection of Aβ species, which are major targets for development of therapeutics for AD.
View Article and Find Full Text PDFDesign and synthesis of isatin derivative payloaded peptide-drug conjugate as tubulin inhibitor against colorectal cancer.
Eur J Med Chem
January 2025
China International Science and Technology Cooperation Base of Food Nutrition/Safety and Medicinal Chemistry, Tianjin University of Science and Technology, Tianjin, 300457, China. Electronic address:
A series of isatin derivatives which could inhibit colorectal cancer (CRC) were synthesized. Among those compounds, 5B exhibited good inhibitory activity of CRC through the inhibition of tubulin expression, inducing apoptosis, and causing G2/M phase cell cycle arrest pathway, which suggested that 5B could be a potential tubulin inhibitor. Based on that, a novel peptide-drug conjugate (PDC), which employed the CRC cells related receptor CD44 ligand peptide A6 coupling to 5B to accomplish A6-5B.
View Article and Find Full Text PDFSynthesis and biological assessment of BUB1B inhibitors for the treatment of clear cell renal cell carcinoma.
Eur J Med Chem
January 2025
Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, SE, 17165, Sweden; Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, SE1 9RT, UK. Electronic address:
Clear cell renal cell carcinoma (ccRCC) presents substantial therapeutic challenges due to its molecular heterogeneity, limited response to conventional therapies, and widespread drug resistance. Recent advancements in molecular research have identified novel targets, such as BUB1B, which has been identified through global transcriptomic profiling and gene co-expression network analysis as critical in ccRCC progression. In this study, we synthesized 40 novel derivatives of TG-101209 to modulate BUB1B expression and activity, leading to the induction of apoptosis in Caki-1 cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!